ABOS Acumen Pharmaceuticals, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1576885 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY22.0%
TTM EPS YoY29.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-162.7%
ROA-91.3%
ROIC (approx.)-195.6%
Asset turnover—
Leverage & solvency
Liabilities / assets59.6%
Debt / equity0.76x
Current ratio1.89x
Interest coverage-24.65x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $104.89M | $93.80M |
| SG&A expense | $18.95M | $20.22M |
| Operating income | -$123.83M | -$114.02M |
| Interest expense | $4.22M | $4.07M |
| Income tax | $0 | $0 |
| Net income | -$121.33M | -$102.33M |
| EBITDA | -$123.77M | -$113.95M |
| EPS (basic) | -2.00 | -1.71 |
| EPS (diluted) | -2.00 | -1.71 |
| Weighted avg. shares (diluted) | 60.56M | 60.01M |
| Balance sheet | ||
| Cash & equivalents | $53.99M | $35.86M |
| Short-term investments | $62.88M | $135.93M |
| Current assets | $122.25M | $178.31M |
| PP&E, net | $103,000 | $73,000 |
| Total assets | $122.83M | $238.99M |
| Current liabilities | $30.01M | $27.61M |
| Short-term debt | $8.77M | $0 |
| Long-term debt | $22.40M | $29.42M |
| Total debt | $31.16M | $29.42M |
| Total liabilities | $52.40M | $57.18M |
| Shareholders' equity | $70.43M | $181.82M |
| Net debt | -$22.83M | -$6.44M |
| Shares outstanding | 60.58M | 60.09M |
| Cash flow statement | ||
| Operating cash flow | -$115.54M | -$86.22M |
| Capital expenditure | $88,000 | $16,000 |
| Free cash flow | -$115.63M | -$86.23M |
| Investing cash flow | $133.93M | $48.03M |
| Financing cash flow | -$34,000 | $6.93M |
| Depreciation & amortization | $58,000 | $63,000 |
| Stock-based compensation | $9.85M | $9.63M |
Free plan shows the latest 2 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.